Skip to main content
main-content
Erschienen in: Endocrine 2/2020

09.06.2020 | Original Article

Partial empty sella syndrome, GH deficiency and transient central adrenal insufficiency in a patient with NF1

verfasst von: Eleni Magdalini Kyritsi, Maria Hasiotou, Christina Kanaka-Gantenbein

Erschienen in: Endocrine | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To describe the case of a 9-year-old male patient with neurofibromatosis type 1 (NF1), partial empty sella (PES), transient central adrenal insufficiency (CAI) and growth hormone (GH) deficiency (GHD) treated with recombinant GH (rGH).

Methods

The diagnosis of GHD was established upon peak GH response <10 ng/mL following glucagon and clonidine stimulation tests. CAI was diagnosed when peak cortisol response was <18 μg/dL following 1 μg Synacthen test (ST) with normal ACTH levels.

Results

The diagnosis of NF1 was made at the age of 1.5 year. The patient first attended our Department at the age of 4.5 years. He presented with short stature (height: 95 cm < 3rd percentile), macrocephaly, frontal bossing, café-au-lait spots and bilateral proptosis. His growth rate (GR) initially was 5.3 cm/year. Brain/pituitary MRI showed T2-hyperintensities typical for NF1 and PES with reduced pituitary gland height (3 mm). The pituitary function tests revealed GHD. During follow-up his imaging findings remained unchanged, while his GR decelerated. He was started on rGH at the age of 8.5 years. Within the following year he grew 8.7 cm in height and could preserve a normal GR thereafter. At the age of 10.3 years, he was diagnosed with CAI (maximum cortisol response post-1 μg ST: 13.1 μg/dL). Ηe received hydrocortisone for 1 year. A repeat 1 μg ST off hydrocortisone showed normal cortisol response. During follow-up, brain MRI findings remained stable, while his pituitary demonstrated normal size and signal intensity.

Conclusion

Empty sella and hypopituitarism may occur in the context of NF1. Short stature may be associated with GHD in the absence of intrasellar masses in affected individuals. Lifelong endocrine follow-up is recommended for all NF1 patients.
Literatur
1.
Zurück zum Zitat A.C. Hirbe, D.H. Gutmann, Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol. 13(8), 834–843 (2014) PubMed A.C. Hirbe, D.H. Gutmann, Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol. 13(8), 834–843 (2014) PubMed
2.
Zurück zum Zitat V.C. Williams, J. Lucas, M.A. Babcock, D.H. Gutmann, B. Korf, B.L. Maria, Neurofibromatosis type 1 revisited. Pediatrics 123(1), 124–133 (2009) PubMed V.C. Williams, J. Lucas, M.A. Babcock, D.H. Gutmann, B. Korf, B.L. Maria, Neurofibromatosis type 1 revisited. Pediatrics 123(1), 124–133 (2009) PubMed
3.
Zurück zum Zitat B. Hegedus, T.H. Yeh, D.Y. Lee, R.J. Emnett, J. Li, D.H. Gutmann, Neurofibromin regulates somatic growth through the hypothalamic-pituitary axis. Hum. Mol. Genet. 17(19), 2956–2966 (2008) PubMedPubMedCentral B. Hegedus, T.H. Yeh, D.Y. Lee, R.J. Emnett, J. Li, D.H. Gutmann, Neurofibromin regulates somatic growth through the hypothalamic-pituitary axis. Hum. Mol. Genet. 17(19), 2956–2966 (2008) PubMedPubMedCentral
4.
Zurück zum Zitat Y.S. Yap, J.R. McPherson, C.K. Ong, S.G. Rozen, B.T. Teh, A.S. Lee, D.F. Callen, The NF1 gene revisited—from bench to bedside. Oncotarget 5(15), 5873–5892 (2014) PubMedPubMedCentral Y.S. Yap, J.R. McPherson, C.K. Ong, S.G. Rozen, B.T. Teh, A.S. Lee, D.F. Callen, The NF1 gene revisited—from bench to bedside. Oncotarget 5(15), 5873–5892 (2014) PubMedPubMedCentral
5.
Zurück zum Zitat S. El-Watidy, A. Jamjoom, Z.A. Jamjoom, W. Selen, Cranio-orbital anomalies in Von Recklinghausen neurofibromatosis simulating an intraorbital space-occupying lesion. Ann. Saudi. Med. 15(4), 399–401 (1995) PubMed S. El-Watidy, A. Jamjoom, Z.A. Jamjoom, W. Selen, Cranio-orbital anomalies in Von Recklinghausen neurofibromatosis simulating an intraorbital space-occupying lesion. Ann. Saudi. Med. 15(4), 399–401 (1995) PubMed
6.
Zurück zum Zitat E.A. Soucy, D. van Oppen, N.L. Nejedly, F. Gao, D.H. Gutmann, A.S. Hollander, Height assessments in children with neurofibromatosis type 1. J. Child. Neurol. 28(3), 303–307 (2013) PubMed E.A. Soucy, D. van Oppen, N.L. Nejedly, F. Gao, D.H. Gutmann, A.S. Hollander, Height assessments in children with neurofibromatosis type 1. J. Child. Neurol. 28(3), 303–307 (2013) PubMed
7.
Zurück zum Zitat M. Clementi, S. Milani, I. Mammi, S. Boni, C. Monciotti, R. Tenconi, Neurofibromatosis type 1 growth charts. Am. J. Med. Genet. 87(4), 317–323 (1999) PubMed M. Clementi, S. Milani, I. Mammi, S. Boni, C. Monciotti, R. Tenconi, Neurofibromatosis type 1 growth charts. Am. J. Med. Genet. 87(4), 317–323 (1999) PubMed
8.
Zurück zum Zitat J. Szudek, P. Birch, J.M. Friedman, Growth in North American white children with neurofibromatosis 1 (NF1). J. Med. Genet. 37(12), 933–938 (2000) PubMedPubMedCentral J. Szudek, P. Birch, J.M. Friedman, Growth in North American white children with neurofibromatosis 1 (NF1). J. Med. Genet. 37(12), 933–938 (2000) PubMedPubMedCentral
9.
Zurück zum Zitat R. Vassilopoulou-Sellin, M.J. Klein, J.K. Slopis, Growth hormone deficiency in children with neurofibromatosis type 1 without suprasellar lesions. Pediatr. Neurol. 22(5), 355–358 (2000) PubMed R. Vassilopoulou-Sellin, M.J. Klein, J.K. Slopis, Growth hormone deficiency in children with neurofibromatosis type 1 without suprasellar lesions. Pediatr. Neurol. 22(5), 355–358 (2000) PubMed
10.
Zurück zum Zitat S.J. Howell, P. Wilton, A. Lindberg, S.M. Shalet, Growth hormone replacement and the risk of malignancy in children with neurofibromatosis. J. Pediatr. 133(2), 201–205 (1998) PubMed S.J. Howell, P. Wilton, A. Lindberg, S.M. Shalet, Growth hormone replacement and the risk of malignancy in children with neurofibromatosis. J. Pediatr. 133(2), 201–205 (1998) PubMed
12.
Zurück zum Zitat S. Raman, A. Grimberg, S.G. Waguespack, B.S. Miller, C.A. Sklar, L.R. Meacham, B.C. Patterson, Risk of neoplasia in pediatric patients receiving growth hormone therapy–a report from the Pediatric Endocrine Society Drug and Therapeutics Committee. J. Clin. Endocrinol. Metab. 100(6), 2192–2203 (2015) PubMedPubMedCentral S. Raman, A. Grimberg, S.G. Waguespack, B.S. Miller, C.A. Sklar, L.R. Meacham, B.C. Patterson, Risk of neoplasia in pediatric patients receiving growth hormone therapy–a report from the Pediatric Endocrine Society Drug and Therapeutics Committee. J. Clin. Endocrinol. Metab. 100(6), 2192–2203 (2015) PubMedPubMedCentral
13.
Zurück zum Zitat C. Bizzarri, G. Bottaro, Endocrine implications of neurofibromatosis 1 in childhood. Horm. Res. Paediatr. 83(4), 232–241 (2015) PubMed C. Bizzarri, G. Bottaro, Endocrine implications of neurofibromatosis 1 in childhood. Horm. Res. Paediatr. 83(4), 232–241 (2015) PubMed
14.
Zurück zum Zitat I. Sani, A. Albanese, Endocrine long-term follow-up of children with neurofibromatosis type 1 and optic pathway glioma. Horm. Res. Paediatr. 87(3), 179–188 (2017) PubMed I. Sani, A. Albanese, Endocrine long-term follow-up of children with neurofibromatosis type 1 and optic pathway glioma. Horm. Res. Paediatr. 87(3), 179–188 (2017) PubMed
15.
Zurück zum Zitat D. Carmi, M. Shohat, A. Metzker, Z. Dickerman, Growth, puberty, and endocrine functions in patients with sporadic or familial neurofibromatosis type 1: a longitudinal study. Pediatrics. 103(6 Pt 1), 1257–1262 (1999) PubMed D. Carmi, M. Shohat, A. Metzker, Z. Dickerman, Growth, puberty, and endocrine functions in patients with sporadic or familial neurofibromatosis type 1: a longitudinal study. Pediatrics. 103(6 Pt 1), 1257–1262 (1999) PubMed
16.
Zurück zum Zitat R. Virdis, M.E. Street, M.A. Bandello, C. Tripodi, A. Donadio, A.R. Villani, L. Cagozzi, L. Garavelli, S. Bernasconi, Growth and pubertal disorders in neurofibromatosis type 1. J. Pediatr. Endocrinol. Metab. 16(Suppl 2), 289–292 (2003) PubMed R. Virdis, M.E. Street, M.A. Bandello, C. Tripodi, A. Donadio, A.R. Villani, L. Cagozzi, L. Garavelli, S. Bernasconi, Growth and pubertal disorders in neurofibromatosis type 1. J. Pediatr. Endocrinol. Metab. 16(Suppl 2), 289–292 (2003) PubMed
17.
Zurück zum Zitat M.L. Iezzi, G. Varriale, L. Zagaroli, M. Greco, S. Lasorella, A. Verrotti di Pianella, Growth hormone deficit as a first clinical manifestation of early diffuse cerebral glioma in patient with neurofibromatosis. Ann. Clin. Lab. Res. 5, 1 (2017) M.L. Iezzi, G. Varriale, L. Zagaroli, M. Greco, S. Lasorella, A. Verrotti di Pianella, Growth hormone deficit as a first clinical manifestation of early diffuse cerebral glioma in patient with neurofibromatosis. Ann. Clin. Lab. Res. 5, 1 (2017)
18.
Zurück zum Zitat M.H. Cnossen, E.N. Stam, L.C. Cooiman, H.J. Simonsz, H. Stroink, A.P. Oranje, D.J. Halley, A. de Goede-Bolder, M.F. Niermeijer, S.M.de Muinck Keizer-Schrama, Endocrinologic disorders and optic pathway gliomas in children with neurofibromatosis type 1. Pediatrics 100(4), 667–670 (1997). PubMed M.H. Cnossen, E.N. Stam, L.C. Cooiman, H.J. Simonsz, H. Stroink, A.P. Oranje, D.J. Halley, A. de Goede-Bolder, M.F. Niermeijer, S.M.de Muinck Keizer-Schrama, Endocrinologic disorders and optic pathway gliomas in children with neurofibromatosis type 1. Pediatrics 100(4), 667–670 (1997). PubMed
19.
Zurück zum Zitat A.R. Shepard, W. Zhang, N.L. Eberhardt, Two CGTCA motifs and a GHF1/Pit1 binding site mediate cAMP-dependent protein kinase a regulation of human growth hormone gene expression in rat anterior pituitary GC cells. J. Biol. Chem. 269(3), 1804–1814 (1994) PubMed A.R. Shepard, W. Zhang, N.L. Eberhardt, Two CGTCA motifs and a GHF1/Pit1 binding site mediate cAMP-dependent protein kinase a regulation of human growth hormone gene expression in rat anterior pituitary GC cells. J. Biol. Chem. 269(3), 1804–1814 (1994) PubMed
20.
Zurück zum Zitat B. Dasgupta, L.L. Dugan, D.H. Gutmann, The neurofibromatosis 1 gene product neurofibromin regulates pituitary adenylate cyclase-activating polypeptide-mediated signaling in astrocytes. J. Neurosci. 23(26), 8949–8954 (2003) PubMedPubMedCentral B. Dasgupta, L.L. Dugan, D.H. Gutmann, The neurofibromatosis 1 gene product neurofibromin regulates pituitary adenylate cyclase-activating polypeptide-mediated signaling in astrocytes. J. Neurosci. 23(26), 8949–8954 (2003) PubMedPubMedCentral
21.
Zurück zum Zitat E.H. Burrows, Bone changes in orbital neurofibromatosis. Br. J. Radiol. 36, 549–561 (1963) PubMed E.H. Burrows, Bone changes in orbital neurofibromatosis. Br. J. Radiol. 36, 549–561 (1963) PubMed
22.
Zurück zum Zitat S.K. Gupta, H.V. Nema, P.L. Bhatia, K. Sasibabu, R. Kesharwani, The radiological features of craniofacial neurofibromatosis. Clin. Radiol. 30(5), 553–557 (1979) PubMed S.K. Gupta, H.V. Nema, P.L. Bhatia, K. Sasibabu, R. Kesharwani, The radiological features of craniofacial neurofibromatosis. Clin. Radiol. 30(5), 553–557 (1979) PubMed
23.
Zurück zum Zitat R.L. Agrawal, S. Bhargava, A.H. Samma, A.K. Kothari, H.K. Bedi, R.L. Shrimali, Empty sella syndrome with neurofibromatosis. Indian J. Ophthalmol. 24(4), 38–40 (1977) PubMed R.L. Agrawal, S. Bhargava, A.H. Samma, A.K. Kothari, H.K. Bedi, R.L. Shrimali, Empty sella syndrome with neurofibromatosis. Indian J. Ophthalmol. 24(4), 38–40 (1977) PubMed
24.
Zurück zum Zitat D. Miljic, S. Pekic, V. Popovic, Empty sella. In Endotext [Internet], eds by K.R. Feingold, B. Anawalt, A. Boyce, G. Chrousos, K. Dungan, A. Grossman, J.M. Hershman, G. Kaltsas, C. Koch, P. Kopp, M. Korbonits, R. McLachlan, J.E. Morley, M. New, L. Perreault, J. Purnell, R. Rebar, F. Singer, D.L. Trence, A. Vinik, D.P. Wilson (MDText.com, Inc, South Dartmouth, MA, 2018) D. Miljic, S. Pekic, V. Popovic, Empty sella. In Endotext [Internet], eds by K.R. Feingold, B. Anawalt, A. Boyce, G. Chrousos, K. Dungan, A. Grossman, J.M. Hershman, G. Kaltsas, C. Koch, P. Kopp, M. Korbonits, R. McLachlan, J.E. Morley, M. New, L. Perreault, J. Purnell, R. Rebar, F. Singer, D.L. Trence, A. Vinik, D.P. Wilson (MDText.com, Inc, South Dartmouth, MA, 2018)
25.
Zurück zum Zitat L. De Marinis, S. Bonadonna, A. Bianchi, G. Maira, A. Giustina, Primary empty sella. J. Clin. Endocrinol. Metab. 90(9), 5471–5477 (2005) PubMed L. De Marinis, S. Bonadonna, A. Bianchi, G. Maira, A. Giustina, Primary empty sella. J. Clin. Endocrinol. Metab. 90(9), 5471–5477 (2005) PubMed
26.
Zurück zum Zitat S. Chiloiro, A. Giampietro, A. Bianchi, T. Tartaglione, A. Capobianco, C. Anile, L. De Marinis, Diagnosis of endocrine disease: primary empty sella: a comprehensive review. Eur. J. Endocrinol. 177(6), R275–R285 (2017) PubMed S. Chiloiro, A. Giampietro, A. Bianchi, T. Tartaglione, A. Capobianco, C. Anile, L. De Marinis, Diagnosis of endocrine disease: primary empty sella: a comprehensive review. Eur. J. Endocrinol. 177(6), R275–R285 (2017) PubMed
27.
Zurück zum Zitat A.M. Lenz, A.W. Root, Empty sella syndrome. Pediatr. Endocrinol. Rev. 9(4), 710–715 (2012) PubMed A.M. Lenz, A.W. Root, Empty sella syndrome. Pediatr. Endocrinol. Rev. 9(4), 710–715 (2012) PubMed
28.
Zurück zum Zitat D. Rath, R.K. Sahoo, J. Choudhury, D.K. Dash, A. Mohapatra, Empty sella syndrome in a male child with failure to thrive. J. Pediatr. Neurosci. 10(1), 45–47 (2015) PubMedPubMedCentral D. Rath, R.K. Sahoo, J. Choudhury, D.K. Dash, A. Mohapatra, Empty sella syndrome in a male child with failure to thrive. J. Pediatr. Neurosci. 10(1), 45–47 (2015) PubMedPubMedCentral
29.
Zurück zum Zitat R.E. Ferner, D.H. Gutmann, Neurofibromatosis type 1 (NF1): diagnosis and management. Handb. Clin. Neurol. 115, 939–955 (2013) PubMed R.E. Ferner, D.H. Gutmann, Neurofibromatosis type 1 (NF1): diagnosis and management. Handb. Clin. Neurol. 115, 939–955 (2013) PubMed
30.
Zurück zum Zitat P. Julayanont, A. Karukote, D. Ruthirago, D. Panikkath, R. Panikkath, Idiopathic intracranial hypertension: ongoing clinical challenges and future prospects. J. Pain. Res. 9, 87–99 (2016) PubMedPubMedCentral P. Julayanont, A. Karukote, D. Ruthirago, D. Panikkath, R. Panikkath, Idiopathic intracranial hypertension: ongoing clinical challenges and future prospects. J. Pain. Res. 9, 87–99 (2016) PubMedPubMedCentral
31.
Zurück zum Zitat A.L. Gilbert, G. Heidary, Update on the evaluation of pediatric idiopathic intracranial hypertension. Curr. Opin. Ophthalmol. 27(6), 493–497 (2016) PubMed A.L. Gilbert, G. Heidary, Update on the evaluation of pediatric idiopathic intracranial hypertension. Curr. Opin. Ophthalmol. 27(6), 493–497 (2016) PubMed
32.
Zurück zum Zitat B. Shofty, L. Ben-Sira, S. Constantini, S. Freedman, A. Kesler, Optic nerve sheath diameter on MR imaging: establishment of norms and comparison of pediatric patients with idiopathic intracranial hypertension with healthy controls. AJNR Am. J. Neuroradiol. 33(2), 366–369 (2012) PubMed B. Shofty, L. Ben-Sira, S. Constantini, S. Freedman, A. Kesler, Optic nerve sheath diameter on MR imaging: establishment of norms and comparison of pediatric patients with idiopathic intracranial hypertension with healthy controls. AJNR Am. J. Neuroradiol. 33(2), 366–369 (2012) PubMed
33.
Zurück zum Zitat T. Mushtaq, F. Shakur, J.K. Wales, N.P. Wright, Reliability of the low dose synacthen test in children undergoing pituitary function testing. J. Pediatr. Endocrinol. Metab. 21(12), 1129–1132 (2008) PubMed T. Mushtaq, F. Shakur, J.K. Wales, N.P. Wright, Reliability of the low dose synacthen test in children undergoing pituitary function testing. J. Pediatr. Endocrinol. Metab. 21(12), 1129–1132 (2008) PubMed
34.
Zurück zum Zitat M.C. Raux Demay, J.P. Magny, N. Idrès, A. Grimfeld, Y. Le Bouc, Use of the low-dose corticotropin stimulation test for the monitoring of children with asthma treated with inhaled corticosteroids. Horm. Res. 66(2), 51–60 (2006) PubMed M.C. Raux Demay, J.P. Magny, N. Idrès, A. Grimfeld, Y. Le Bouc, Use of the low-dose corticotropin stimulation test for the monitoring of children with asthma treated with inhaled corticosteroids. Horm. Res. 66(2), 51–60 (2006) PubMed
35.
Zurück zum Zitat L.M. Mongioì, R.A. Condorelli, F. Barbagallo, R. Cannarella, S. La Vignera, A.E. Calogero, Accuracy of the low-dose ACTH stimulation test for adrenal insufficiency diagnosis: a re-assessment of the cut-off value. J. Clin. Med. 8(6), pii: E806 (2019) L.M. Mongioì, R.A. Condorelli, F. Barbagallo, R. Cannarella, S. La Vignera, A.E. Calogero, Accuracy of the low-dose ACTH stimulation test for adrenal insufficiency diagnosis: a re-assessment of the cut-off value. J. Clin. Med. 8(6), pii: E806 (2019)
36.
Zurück zum Zitat M. Wade, S. Baid, K. Calis, H. Raff, N. Sinaii, L. Nieman, Technical details influence the diagnostic accuracy of the 1 microg ACTH stimulation test. Eur. J. Endocrinol. 162(1), 109–113 (2010) PubMed M. Wade, S. Baid, K. Calis, H. Raff, N. Sinaii, L. Nieman, Technical details influence the diagnostic accuracy of the 1 microg ACTH stimulation test. Eur. J. Endocrinol. 162(1), 109–113 (2010) PubMed
37.
Zurück zum Zitat A. Ciresi, S. Radellini, E. Vigneri, V. Guarnotta, J. Bianco, M.G. Mineo, C. Giordano, Correlation between adrenal function, growth hormone secretion, and insulin sensitivity in children with idiopathic growth hormone deficiency. J. Endocrinol. Invest. 41(3), 333–342 (2018) PubMed A. Ciresi, S. Radellini, E. Vigneri, V. Guarnotta, J. Bianco, M.G. Mineo, C. Giordano, Correlation between adrenal function, growth hormone secretion, and insulin sensitivity in children with idiopathic growth hormone deficiency. J. Endocrinol. Invest. 41(3), 333–342 (2018) PubMed
38.
Zurück zum Zitat C. Giavoli, R. Libé, S. Corbetta, E. Ferrante, A. Lania, M. Arosio, A. Spada, P. Beck-Peccoz, Effect of recombinant human growth hormone (GH) replacement on the hypothalamic-pituitary-adrenal axis in adult GH-deficient patients. J. Clin. Endocrinol. Metab. 89(11), 5397–5401 (2004) PubMed C. Giavoli, R. Libé, S. Corbetta, E. Ferrante, A. Lania, M. Arosio, A. Spada, P. Beck-Peccoz, Effect of recombinant human growth hormone (GH) replacement on the hypothalamic-pituitary-adrenal axis in adult GH-deficient patients. J. Clin. Endocrinol. Metab. 89(11), 5397–5401 (2004) PubMed
39.
Zurück zum Zitat C. Giavoli, Unmasking other pituitary deficits during growth hormone replacement therapy. Ann. Endocrinol. 68(4), 237–240 (2007) C. Giavoli, Unmasking other pituitary deficits during growth hormone replacement therapy. Ann. Endocrinol. 68(4), 237–240 (2007)
40.
Zurück zum Zitat M. Tschöp, H. Lahner, H. Feldmeier, H. Grasberger, K.M. Morrison, O.E. Janssen, A.F. Attanasio, C.J. Strasburger, Effects of growth hormone replacement therapy on levels of cortisol and cortisol-binding globulin in hypopituitary adults. Eur. J. Endocrinol. 143(6), 769–773 (2000) PubMed M. Tschöp, H. Lahner, H. Feldmeier, H. Grasberger, K.M. Morrison, O.E. Janssen, A.F. Attanasio, C.J. Strasburger, Effects of growth hormone replacement therapy on levels of cortisol and cortisol-binding globulin in hypopituitary adults. Eur. J. Endocrinol. 143(6), 769–773 (2000) PubMed
41.
Zurück zum Zitat L. De Paepe, R. Abs, J. Verlooy, A. Clemens, R.M. Smets, P. Louis, J.J. Martin, Benign intracranial hypertension as a cause of transient partial pituitary deficiency. J. Neurol. Sci. 114(2), 152–155 (1993) PubMed L. De Paepe, R. Abs, J. Verlooy, A. Clemens, R.M. Smets, P. Louis, J.J. Martin, Benign intracranial hypertension as a cause of transient partial pituitary deficiency. J. Neurol. Sci. 114(2), 152–155 (1993) PubMed
42.
Zurück zum Zitat M.T. Zagardo, W.S. Cail, S.E. Kelman, M.I. Rothman, Reversible empty sella in idiopathic intracranial hypertension: an indicator of successful therapy? AJNR Am. J. Neuroradiol. 17(10), 1953–1956 (1996) PubMed M.T. Zagardo, W.S. Cail, S.E. Kelman, M.I. Rothman, Reversible empty sella in idiopathic intracranial hypertension: an indicator of successful therapy? AJNR Am. J. Neuroradiol. 17(10), 1953–1956 (1996) PubMed
43.
Zurück zum Zitat V. Triggiani, V.A. Giagulli, M. Moschetta, E. Guastamacchia, An unusual case of reversible empty sella. Endocr. Metab. Immune Disord. Drug Targets. 16(2), 154–156 (2016) PubMed V. Triggiani, V.A. Giagulli, M. Moschetta, E. Guastamacchia, An unusual case of reversible empty sella. Endocr. Metab. Immune Disord. Drug Targets. 16(2), 154–156 (2016) PubMed
44.
Zurück zum Zitat A. Giustina, G. Aimaretti, M. Bondanelli, F. Buzi, S. Cannavò, S. Cirillo, A. Colao, L. De Marinis, D. Ferone, M. Gasperi, S. Grottoli, T. Porcelli, E. Ghigo, E. degli Uberti, Primary empty sella: why and when to investigate hypothalamic-pituitary function. J. Endocrinol. Invest. 33(5), 343–346 (2010) PubMed A. Giustina, G. Aimaretti, M. Bondanelli, F. Buzi, S. Cannavò, S. Cirillo, A. Colao, L. De Marinis, D. Ferone, M. Gasperi, S. Grottoli, T. Porcelli, E. Ghigo, E. degli Uberti, Primary empty sella: why and when to investigate hypothalamic-pituitary function. J. Endocrinol. Invest. 33(5), 343–346 (2010) PubMed
45.
Zurück zum Zitat R.E. Ferner, S.M. Huson, N. Thomas, C. Moss, H. Willshaw, D.G. Evans, M. Upadhyaya, R. Towers, M. Gleeson, C. Steiger, A. Kirby, Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J. Med. Genet. 44(2), 81–88 (2007) PubMed R.E. Ferner, S.M. Huson, N. Thomas, C. Moss, H. Willshaw, D.G. Evans, M. Upadhyaya, R. Towers, M. Gleeson, C. Steiger, A. Kirby, Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J. Med. Genet. 44(2), 81–88 (2007) PubMed
46.
Zurück zum Zitat K.S. Cunha, E.P. Barboza, E.C. Fonseca, Identification of growth hormone receptor in plexiform neurofibromas of patients with neurofibromatosis type 1. Clinics 63(1), 39–42 (2008) PubMedPubMedCentral K.S. Cunha, E.P. Barboza, E.C. Fonseca, Identification of growth hormone receptor in plexiform neurofibromas of patients with neurofibromatosis type 1. Clinics 63(1), 39–42 (2008) PubMedPubMedCentral
47.
Zurück zum Zitat U. Dagalakis, M. Lodish, E. Dombi, N. Sinaii, J. Sabo, A. Baldwin, S.M. Steinberg, C.A. Stratakis, B.C. Widemann, Puberty and plexiform neurofibroma tumor growth in patients with neurofibromatosis type I. J. Pediatr. 164(3), 620–624 (2014) PubMed U. Dagalakis, M. Lodish, E. Dombi, N. Sinaii, J. Sabo, A. Baldwin, S.M. Steinberg, C.A. Stratakis, B.C. Widemann, Puberty and plexiform neurofibroma tumor growth in patients with neurofibromatosis type I. J. Pediatr. 164(3), 620–624 (2014) PubMed
Metadaten
Titel
Partial empty sella syndrome, GH deficiency and transient central adrenal insufficiency in a patient with NF1
verfasst von
Eleni Magdalini Kyritsi
Maria Hasiotou
Christina Kanaka-Gantenbein
Publikationsdatum
09.06.2020
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 2/2020
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-020-02351-z

Weitere Artikel der Ausgabe 2/2020

Endocrine 2/2020 Zur Ausgabe

Neu im Fachgebiet Innere Medizin

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Innere Medizin und bleiben Sie gut informiert – ganz bequem per eMail.